Article thumbnail

Use and efficacy of bone morphogenetic proteins in fracture healing

By Suzanne N. Lissenberg-Thunnissen, David J. J. de Gorter, Cornelis F. M. Sier and Inger B. Schipper
Topics: Review
Publisher: Springer-Verlag
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2011). 35:1271–1280 1277Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs).
  2. (2006). 35:1271–1280for the use of BMP-2 for spinal surgery in Germany (in German).
  3. (2009). A cost analysis of treatment of tibial fracture nonunionby bonegraftingor bone morphogeneticprotein-7. Int Orthop33:1407–
  4. (2010). A novel TWO-STEP renaturation procedure for efficient production of recombinant BMP-2. Protein Expr Purif 73:65–69
  5. (1995). A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye.
  6. (2008). Application of rhBMP-7 and platelet-rich plasma in the treatment of long bone non-unions: a prospective randomised clinical study on 120 patients.
  7. (2007). Balancing BMP signaling through integrated inputs into the Smad1 linker.
  8. (2007). Biological aspects of bone, cartilage and tendon regeneration.
  9. (2011). Biphasic effects of transforming growth factor-beta on bone morphogenetic protein-induced osteoblast differentiation.
  10. (2006). BMP and BMP inhibitors in bone.
  11. (2009). BMP-13 emerges as a potential inhibitor of bone formation.
  12. (2001). BMP-2 and BMP-9 promotes chondrogenic differentiation of human multipotential mesenchymal cells and overcomes the inhibitory effect of IL-1.
  13. (2009). BMP-2 release and dose-response studies in hydroxyapatite and beta-tricalcium phosphate.
  14. (2010). BMP-2/6 heterodimer is more effective than BMP-2 or BMP-6 homodimers as inductor of differentiation of human embryonic stem cells. PLoS One 5:e11167
  15. (2009). BMP-6 and mesenchymal stem cell differentiation.
  16. (2004). BMP10 is essential for maintaining cardiac growth during murine cardiogenesis.
  17. (2008). BMPER is an endothelial cell regulator and controls bone morphogenetic protein-4-dependent angiogenesis.
  18. (2010). Bone morphogenetic protein (BMP) for fracture healing in adults. Cochrane Database Syst Rev 6: CD006950
  19. (2010). Bone morphogenetic protein receptors and signal transduction.
  20. (1996). Bone morphogenetic protein-1: the type I procollagen Cproteinase.
  21. (2001). Bone morphogenetic protein-3 is a negative regulator of bone density.
  22. (1995). Bone morphogenetic protein-9 binds to liver cells and stimulates proliferation.
  23. (2004). Bone morphogenetic proteins.
  24. (1965). Bone: formation by autoinduction.
  25. (2004). Characterization of the distinct orthotopic bone-forming activity of 14 BMPs using recombinant adenovirus-mediated gene delivery.
  26. (2009). Clinical and radiographic outcomes of posterolateral lumbar spine fusion in humans using recombinant human bone morphogenetic protein-2: an average five-year follow-up study.
  27. (2007). Clinical applications of BMP-7/OP-1 in fractures, nonunions and spinal fusion.
  28. (2007). Clinical effectiveness and cost-effectiveness of bone morphogenetic proteins in the non-healing of fractures and spinal fusion: a systematic review.
  29. (2002). Clinical evaluation of recombinant human bone morphogenetic protein-2. Clin Orthop Relat Res 395:110–120
  30. (2004). Combined bone morphogenetic protein-2 and -7 gene transfer enhances osteoblastic differentiation and spine fusion in a rodent model.
  31. (2010). Comparison of the osteoinductivity of bioimplants containing recombinant human bone morphogenetic proteins 2 (Infuse) and 7 (OP-1). Oral Surg Oral Med Oral Pathol Oral Radiol Endod 109:531–540
  32. (2003). CRIM1 regulates the rate of processing and delivery of bone morphogenetic proteins to the cell surface.
  33. (2011). Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma.
  34. (2007). Current and future clinical applications of bone morphogenetic proteins in orthopaedic trauma surgery.
  35. (2005). Current concepts of molecular aspects of bone healing.
  36. (2002). Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing.
  37. (1995). Discovery and clinical applications of bone morphogenetic proteins.
  38. (2002). Ectopic osteogenesis using adenoviral bone morphogenetic protein (BMP)-4 and BMP-6 gene transfer. Mol Ther 6:464–470
  39. (2011). Effects of protein dose and delivery system on BMP-mediated bone regeneration.
  40. (2004). Endogenous TGF-beta signaling suppresses maturation of osteoblastic mesenchymal cells.
  41. (2010). Endoglin is involved in BMP-2-induced osteogenic differentiation of periodontal ligament cells through a pathway independent of Smad-1/ 5/8 phosphorylation.
  42. (2011). Enhancement of bone morphogenetic protein-2-induced ectopic bone formation by transforming growth factor-beta1. Tissue Eng Part A
  43. (2002). Ex vivo bone morphogenetic protein-9 gene therapy using human mesenchymal stem cells induces spinal fusion in rodents.
  44. (2003). Expression of bone morphogenetic protein 6 in healthy and osteoarthritic human articular chondrocytes and stimulation of matrix synthesis in vitro. Arthritis Rheum 48:2501–
  45. (2009). Expression, purification and osteogenic bioactivity of recombinant human BMP-4, -9, -10, -11 and -14. Protein Expr Purif 63:89–94
  46. (2009). Fracture healing and bone repair: an update.
  47. (2005). Fractures of the tibia and fibula. Rockwood and Green’s fractures in adults. Lippincott Williams
  48. (1995). Growth/differentiationfactor-10:a new member ofthe transforming growth factor-beta superfamily related to bone morphogenetic protein-3. Growth Factors 12:99–109
  49. (2010). Identification of a key residue mediating bone morphogenetic protein (BMP)-6 resistance to noggin inhibition allows for engineered BMPs with superior agonist activity.
  50. (2010). Immunolocalization of BMPs, BMP antagonists, receptors, and effectors during fracture repair.
  51. (2009). Incidence of traumatic longbone fractures requiring in-hospital management: a prospective ageand gender-specific analysis of 4890 fractures.
  52. (2000). Induction and maintenance of the neuronal cholinergic phenotype in the central nervous system by BMP-9.
  53. (2007). Integrating patterning signals:
  54. (1994). Limb alterations in brachypodism mice due to mutations in a new member of the TGF beta-superfamily.
  55. (2004). Localization of bone morphogenetic proteins (BMPs)-2, -4, and -6 within megakaryocytes and platelets.
  56. (2007). Löwik CW, ten Dijke P
  57. (2008). Lowik CW, V an Bezooijen RL
  58. (2007). Molecular aspects of fracture healing: which are the important molecules?
  59. (2001). Morphologic analysis of BMP-9 gene therapy-induced osteogenesis. Hum Gene Ther 12:697–710
  60. (2006). Noggin regulation of bone morphogenetic protein (BMP) 2/7 heterodimer activity in vitro.
  61. (2007). Noggin suppression enhances in vitro osteogenesis and accelerates in vivo bone formation.
  62. (1988). Novel regulators of bone formation: molecular clones and activities.
  63. (1999). Osteogenic activity of OP-1 bone morphogenetic protein (BMP-7) in a human fibular defect.
  64. (2003). Osteogenic potential of five different recombinant human bone morphogenetic protein adenoviral vectors in the rat.
  65. (2006). Osteogenic protein-1 (BMP-7) accelerates healing of scaphoid non-union with proximal pole sclerosis.
  66. (2001). Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions.
  67. (2009). Overexpression of BMP3 in the developing skeleton alters endochondral bone formation resulting in spontaneous rib fractures.
  68. Paralkar VM (2007) BMP-6 exerts its osteoinductive effect through activation of IGF-I and EGF pathways.
  69. (2011). Recombinant human bone morphogenetic protein-2 and pancreatic cancer: a retrospective cohort study. Pharmacoepidemiol Drug Saf
  70. (2002). Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients.
  71. (2005). Regulation of BMP-induced ectopic bone formation by Ahsg.
  72. (2007). RhBMP-7 accelerates the healing in distal tibial fractures treated by external fixation.
  73. (2009). Role of bone morphogenetic proteins and their antagonists in healing of bone fracture.
  74. (2010). Sequential BMP-2/BMP-7 delivery from polyester nanocapsules.
  75. (1999). Silencing of TGF-beta signalling by the pseudoreceptor BAMBI.
  76. (2009). Simvastatin locally applied from a biodegradable coating of osteosynthetic implants improves fracture healing comparable to BMP-2 application.
  77. (1999). Stimulation of bone formation in vitro and in rodents by statins.
  78. (2009). Targeting bone morphogenetic protein antagonists: in vitro and in vivo evidence of their role in bone metabolism. Expert Opin Ther Targets 13:123–137
  79. (2001). TGFbeta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation.
  80. (1997). The Bmp8 gene is expressed in developing skeletal tissue and maps near the Achondroplasia locus on mouse chromosome 4.
  81. (1998). The bone morphogenetic protein 15 gene is X-linked and expressed in oocytes.
  82. (2010). The control of fracture healing and its therapeutic targeting: improving upon nature.
  83. (2007). The health economics of the treatment of long-bone non-unions.
  84. (1992). The mouse short ear skeletal morphogenesis locus is associated with defects in a bone morphogenetic member of the TGF beta superfamily.
  85. (2009). The origin of bmp16, a novel Bmp2/4 relative, retained in teleost fish genomes.
  86. (2006). The role of inhibitory molecules in fracture healing.
  87. (2003). The roles of bone morphogenetic protein (BMP) 12 in stimulating the proliferation and matrix production of human patellar tendon fibroblasts.
  88. (1993). Thesleff I
  89. (2000). Use of bone morphogenetic protein-9 gene therapy to induce spinal arthrodesis in the rodent.
  90. V alentin-Opran A et al (2006) Recombinant human BMP-2 and allograft compared with autogenous bone graft for reconstruction of diaphyseal tibial fractures with cortical defects. A randomized, controlled trial.